Eva Fortea Verdejo
Stock Analyst at Wells Fargo
(4.91)
# 212
Out of 4,478 analysts
90
Total ratings
85.7%
Success rate
52.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eva Fortea Verdejo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZYME Zymeworks | Rated: Buy | $34 → $37 | $25.30 | +46.25% | 7 | Jun 30, 2026 | |
| GMAB Genmab | Rated: Buy | $40 | $28.01 | +42.81% | 7 | Jun 29, 2026 | |
| NUVL Nuvalent | Downgraded: Hold | $116 → $124 | $123.72 | +0.23% | 3 | Jun 10, 2026 | |
| CELC Celcuity | Rated: Buy | $183 → $166 | $108.58 | +52.88% | 5 | Jun 3, 2026 | |
| RVMD Revolution Medicines | Rated: Buy | $167 | $189.99 | -12.10% | 10 | Jun 1, 2026 | |
| BCAX Bicara Therapeutics | Rated: Hold | $16 | $29.22 | -45.24% | 10 | Jun 1, 2026 | |
| RLAY Relay Therapeutics | Maintained: Buy | $21 | $18.90 | +11.11% | 9 | May 19, 2026 | |
| ZNTL Zentalis Pharmaceuticals | Rated: Hold | $5 | $4.72 | +5.93% | 1 | May 13, 2026 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintained: Buy | $53 → $57 | $62.77 | -9.19% | 14 | Apr 29, 2026 | |
| IDYA IDEAYA Biosciences | Maintained: Buy | $44 → $48 | $39.49 | +21.57% | 5 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $60 | $31.97 | +87.68% | 3 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $8 → $27 | $30.61 | -11.79% | 2 | Mar 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $30 → $23 | $29.98 | -23.28% | 8 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $27 | $14.90 | +81.21% | 6 | Oct 23, 2025 |
Zymeworks
Jun 30, 2026
Rated: Buy
Price Target: $34 → $37
Current: $25.30
Upside: +46.25%
Genmab
Jun 29, 2026
Rated: Buy
Price Target: $40
Current: $28.01
Upside: +42.81%
Nuvalent
Jun 10, 2026
Downgraded: Hold
Price Target: $116 → $124
Current: $123.72
Upside: +0.23%
Celcuity
Jun 3, 2026
Rated: Buy
Price Target: $183 → $166
Current: $108.58
Upside: +52.88%
Revolution Medicines
Jun 1, 2026
Rated: Buy
Price Target: $167
Current: $189.99
Upside: -12.10%
Bicara Therapeutics
Jun 1, 2026
Rated: Hold
Price Target: $16
Current: $29.22
Upside: -45.24%
Relay Therapeutics
May 19, 2026
Maintained: Buy
Price Target: $21
Current: $18.90
Upside: +11.11%
Zentalis Pharmaceuticals
May 13, 2026
Rated: Hold
Price Target: $5
Current: $4.72
Upside: +5.93%
Kiniksa Pharmaceuticals International,
Apr 29, 2026
Maintained: Buy
Price Target: $53 → $57
Current: $62.77
Upside: -9.19%
IDEAYA Biosciences
Apr 14, 2026
Maintained: Buy
Price Target: $44 → $48
Current: $39.49
Upside: +21.57%
Apr 14, 2026
Maintained: Buy
Price Target: $60
Current: $31.97
Upside: +87.68%
Mar 24, 2026
Upgraded: Buy
Price Target: $8 → $27
Current: $30.61
Upside: -11.79%
Feb 12, 2026
Downgraded: Hold
Price Target: $30 → $23
Current: $29.98
Upside: -23.28%
Oct 23, 2025
Maintained: Buy
Price Target: $27
Current: $14.90
Upside: +81.21%